Copyright
©The Author(s) 2018.
World J Gastroenterol. Oct 14, 2018; 24(38): 4403-4411
Published online Oct 14, 2018. doi: 10.3748/wjg.v24.i38.4403
Published online Oct 14, 2018. doi: 10.3748/wjg.v24.i38.4403
Table 1 Characteristics at waiting list registration between hepatitis C virus and non- hepatitis C virus patients
HCV n = 490 (%) | Non-HCV n = 704 (%) | P value | |
Age (yr) | 56 ± 7.8 | 55 ± 10 | ns |
Gender (male) | 393 (80) | 532 (75.5) | ns |
BMI | 25 ± 4 | 25 ± 4 | ns |
Blood group | ns | ||
0 | 206 (42) | 311 (44.2) | |
A | 199 (40.6) | 282 (40) | |
AB | 19 (3.8) | 30 (4.3) | |
B | 66 (13.4) | 81 (11.5) | |
HCC (yes) | 303 (61.8) | 295 (42) | 0.001 |
Child-Pugh classes | 0.04 | ||
A | 137 (28) | 163 (23) | |
B | 185 (38) | 252 (36) | |
C | 168 (34) | 289 (41) | |
MELD at WL registration | 15 ± 6 | 16.7 ± 6.8 | 0.01 |
Table 2 Characteristics of hepatitis C virus patients at waiting list registration before and after direct-acting antiviral introduction, according to indication to waiting list registration (decompensated liver disease or hepatocellular carcinoma)
dec-HCV | HCV/HCC | |||||
Pre-DAA n = 181 (%) | Post-DAA n = 70 (%) | P value | Pre-DAA n = 144 (%) | Post-DAA n = 94 (%) | P value | |
Gender (male) | 139 (77) | 53 (75.7) | ns | 118 (82) | 82 (87) | ns |
Age (yr) | 55 ± 8 | 55 ± 9 | ns | 57 ± 7 | 59 ± 6 | 0.03 |
BMI | 25 ± 3 | 25 ± 4 | ns | 24.7 ± 3 | 25 ± 3.6 | ns |
Refractory ascites (yes) | 74 (40) | 32 (45.7) | ns | - | - | |
Blood group | ns | ns | ||||
0 | 86 (47.8) | 32 (45.7) | 62 (43) | 35 (39) | ||
A | 70 (38.4) | 25 (35.7) | 52 (36) | 42 (44) | ||
AB | 4 (2.2) | 4 (5.7) | 6 (4) | 5 (5) | ||
B | 21 (11.5) | 9 (12.8) | 24 (17) | 12 (12) | ||
HCC (yes) | 41 (22.5) | 24 (34.2) | ns | - | - | |
Comorbidities | ns | ns | ||||
None | 134 (74.1) | 44 (62.8) | 104 (72.2) | 76 (80) | ||
HBV | 7 (3.8) | 2 (2.8) | 8 (5.5) | 3 (3.2) | ||
Alcohol | 34 (18.6) | 19 (27.1) | 26 (18) | 10 (10.6) | ||
Metabolic | 6 (3.2) | 5 (7.3) | 6 (4.3) | 5 (5.3) | ||
Child-Pugh classes | ns | 0.01 | ||||
A | 6 (3.3) | 3 (4.2) | 64 (44.5) | 64 (68) | ||
B | 67 (37) | 25 (35.7) | 67 (46.5) | 26 (27) | ||
C | 108 (59.6) | 42 (60) | 13 (9) | 4 (4) | ||
MELD score | 18.7 ± 6 | 19.3 ± 6 | ns | 11 ± 3.5 | 11 ± 3.4 | ns |
HCV Genotype1 | ns | ns | ||||
1a | 18 (15.1) | 14 (23) | 11 (10.2) | 16 (18.8) | ||
1b | 68 (57.1) | 34 (55.7) | 67 (62) | 39 (45.8) | ||
2 | 12 (10) | 3 (4.9) | 10 (9.3) | 4 (4.7) | ||
3 | 16 (13.4) | 6 (9.8) | 15 (13.9) | 22 (25.8) | ||
4 | 5 (3.3) | 4 (6.5) | 5 (4.6) | 4 (4.7) | ||
SVR achievement | ||||||
None | 159 (87.8) | 39 (55.7) | 128 (89) | 45 (47.8) | ||
Before WL registration | 13 (7.1) | 17 (24.2) | 0.004 | 10 (7) | 24 (25.5) | 0.001 |
IFN based | 13 (7.1) | 2 (2.8) | 10 (7) | 6 (6.3) | ||
During WL registration | 9 (4.9) | 14 (20) | 0.009 | 6 (4) | 25 (26.5) | 0.001 |
Table 3 Characteristics at the time of liver transplantation between hepatitis C virus and non-hepatitis C virus patients n (%)
HCV n = 289 | Non-HCV n = 377 | P value | |
Age (yr) | 57 ± 7.5 | 55 ± 10 | 0.02 |
Gender (male) | 240 (83) | 288 (76) | 0.04 |
Blood group | ns | ||
0 | 118 (40.8) | 167 (44.2) | |
A | 124 (43) | 147 (39) | |
AB | 12 (4.1) | 19 (5) | |
B | 35 (12.1) | 44 (11.8) | |
Child-Pugh classes | |||
A | 82 (25) | 84 (22.2) | |
B | 99 (36.7) | 116 (30.7) | 0.03 |
C | 108 (38.2) | 177 (47) | |
MELD score | 17 ± 8 | 19 ± 8 | 0.01 |
Waiting time (mo) | 9.6 ± 12 | 10 ± 14 | ns |
Table 4 Characteristics of hepatitis C virus patients at liver transplantation before and after direct-acting antiviral introduction, according to indication to waiting list registration (decompensated liver disease or hepatocellular carcinoma) n (%)
dec-HCV | HCV/HCC | |||||
Pre-DAA n = 91 | Post-DAA n = 51 | P value | Pre-DAA n = 89 | Post-DAA n = 58 | P value | |
Gender (male) | 74 (81) | 40 (78.4) | ns | 77 (86.5) | 49 (84.5) | ns |
Age (yr) | 54.8 ± 8 | 56 ± 8 | ns | 57 ± 7 | 58 ± 7 | ns |
Refractory ascites (yes) | 37 (40.6) | 27 (53) | ns | - | - | |
Blood group | ns | ns | ||||
0 | 41 (45) | 21 (41.7) | 37 (41.5) | 19 (32.7) | ||
A | 35 (38) | 22 (43.3) | 39 (43.8) | 28 (54.9) | ||
AB | 3 (3.3) | 3 (5.8) | 4 (4.5) | 2 (3.4) | ||
B | 12 (13) | 5 (9.8) | 9 (10.2) | 9 (15.5) | ||
HCC (yes) | 19 (20.8) | 19 (37.3) | 0.04 | - | - | |
Child-Pugh classes | ns | 0.001 | ||||
A | 3 (3.2) | 1 (1.9) | 38 (42.6) | 42 (72.4) | ||
B | 27 (29.6) | 17 (33.3) | 42 (47.2) | 12 (20.6) | ||
C | 61 (67.1) | 33 (64.7) | 9 (10) | 4 (6.8) | ||
MELD at LT | 24 ± 6.5 | 23 ± 7.5 | ns | 11.7 ± 4 | 11.2 ± 3 | ns |
SVR at time of LT (yes) | 8 (8.8) | 15 (29.4) | 0.002 | 10 (11) | 24 (41) | 0.0001 |
SVR after IFN-based regimens | 7 (7.6) | 2 (3.9) | 9 (10.1) | 1 (1.7) | ||
Waiting time (mo) | 8.3 ± 12 | 10.6 ± 12 | ns | 9 ± 7.7 | 10 ± 11 | ns |
Table 5 Characteristics of hepatitis C virus patients who achieved sustained virological response after treatment with direct-acting antivirals while in the waiting list n (%)
SVR after DAA before the WL n = 34 | SVR after DAA in the WL n = 54 | |
Age (yr) | 58 ± 8 | 57.7 ± 8 |
Gender (male) | 25 (73.5) | 43 (79.6) |
dec-HCV (yes) | 15 (44) | 44 (44.4) |
MELD score before treament | - | 13 ± 5 |
HCV genotype | ||
1a | 6 (17.6) | 6 (11) |
1b | 17 (50) | 34 (63) |
2 | 2 (5.8) | 2 (3.7) |
3 | 7 (20.5) | 7 (13) |
4 | 2 (5.8) | 5 (9.3) |
Treatment regimens | ||
Sofosbuvir | 4 (11.7) | 27 (50) |
Sofosbuvir/Ledipasvir | 23 (67.6) | 18 (33.3) |
Sofosbuvir/Daclatasvir | 3 (8.8) | 3 (5.5) |
Sofosbuvir/Simeprevir | 1 (2.9) | 4 (7.4) |
Other | 5 (14.7) | 2 (3.7) |
Ribavirin use (yes) | 1 (2.9) | 37 (68.5) |
MELD score after treament | 12.3 ± 4 | 13 ± 6 |
Outcome | ||
Waiting for LT | 16 (47) | 6 (11) |
Delisted | 1 (2.9) | 10 (18.5) |
LT | 10 (29.4) | 28 (51.8) |
Drop out | 5 (14.7) | 2 (3.7) |
Dead | 2 (5.8) | 8 (14.8) |
- Citation: Ferrarese A, Germani G, Gambato M, Russo FP, Senzolo M, Zanetto A, Shalaby S, Cillo U, Zanus G, Angeli P, Burra P. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. World J Gastroenterol 2018; 24(38): 4403-4411
- URL: https://www.wjgnet.com/1007-9327/full/v24/i38/4403.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i38.4403